Artykuły w czasopismach na temat „PTX”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „PTX”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Ito, Ichiaki, Abdelrahman M. G. Yousef, Princess A. Dickson, Keith F. Fournier, Natalie Wall Fowlkes i John Paul Y. C. Shen. "Antitumor activity of intraperitoneal (IP) paclitaxel to mucinous appendiceal adenocarcinoma in orthotopic patient-derived xenograft model." Journal of Clinical Oncology 41, nr 4_suppl (1.02.2023): 151. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.151.
Pełny tekst źródłaKim, Gunzung, Imran Ashraf, Jeongsook Eom i Yongwan Park. "Optimal Path Configuration with Coded Laser Pilots for Charging Electric Vehicles Using High Intensity Laser Power Beams". Applied Sciences 11, nr 9 (23.04.2021): 3826. http://dx.doi.org/10.3390/app11093826.
Pełny tekst źródłaBorghese, Cinzia, Naike Casagrande, Giuseppe Corona i Donatella Aldinucci. "Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance". Pharmaceutics 12, nr 5 (27.04.2020): 401. http://dx.doi.org/10.3390/pharmaceutics12050401.
Pełny tekst źródłaLippton, H. L., Q. Hao, T. Hauth i A. Hyman. "Mechanisms of signal transduction for adenosine and ATP in pulmonary vascular bed". American Journal of Physiology-Heart and Circulatory Physiology 262, nr 3 (1.03.1992): H926—H929. http://dx.doi.org/10.1152/ajpheart.1992.262.3.h926.
Pełny tekst źródłaMelloni, Elisabetta, Elena Marchesi, Lorenzo Preti, Fabio Casciano, Erika Rimondi, Arianna Romani, Paola Secchiero, Maria Luisa Navacchia i Daniela Perrone. "Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids". Molecules 27, nr 2 (12.01.2022): 471. http://dx.doi.org/10.3390/molecules27020471.
Pełny tekst źródłaKoeda, Keisuke, Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani, Hironori Tsujimoto, Akihito Tsuji, Eiji Oki i in. "ABSOLUTE: A phase 3 trial of nanoparticle albumin-bound paclitaxel (nab-PTX) versus solvent-based paclitaxel (sb-PTX) in patients with pre-treated advanced gastric cancer (AGC)—Efficacy and QOL results." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): 4010. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4010.
Pełny tekst źródłaHyun, Hoon, Min Park, Gayoung Jo, So Kim, Heung Chun i Dae Yang. "Photo-Cured Glycol Chitosan Hydrogel for Ovarian Cancer Drug Delivery". Marine Drugs 17, nr 1 (10.01.2019): 41. http://dx.doi.org/10.3390/md17010041.
Pełny tekst źródłaWang, Longkun, Chunqian Zhao, Lu Lu, Honglei Jiang, Fengshan Wang i Xinke Zhang. "Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer". International Journal of Molecular Sciences 24, nr 5 (28.02.2023): 4646. http://dx.doi.org/10.3390/ijms24054646.
Pełny tekst źródłaMao, Yukang, Yili Zhang, Zheng Luo, Ruoting Zhan, Hui Xu, Weiwen Chen i Huicai Huang. "Synthesis, Biological Evaluation and Low-Toxic Formulation Development of Glycosylated Paclitaxel Prodrugs". Molecules 23, nr 12 (5.12.2018): 3211. http://dx.doi.org/10.3390/molecules23123211.
Pełny tekst źródłaTang, Bo, Yu Qian, Yi Gou, Gang Cheng i Guihua Fang. "VE-Albumin Core-Shell Nanoparticles for Paclitaxel Delivery to Treat MDR Breast Cancer". Molecules 23, nr 11 (25.10.2018): 2760. http://dx.doi.org/10.3390/molecules23112760.
Pełny tekst źródłaWang, Ying, Ke-Chun Wu, Bing-Xiang Zhao, Xin Zhao, Xin Wang, Su Chen, Shu-Fang Nie, Wei-San Pan, Xuan Zhang i Qiang Zhang. "A Novel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL: Pharmacokinetics, Biodistribution, andIn VivoAntitumor Efficacy and Safety". Journal of Biomedicine and Biotechnology 2011 (2011): 1–10. http://dx.doi.org/10.1155/2011/854872.
Pełny tekst źródłaNakasya, Akio, Yuya Hagiwara, Tatsuki Ikoma, Yusuke Kurioka, Toshihiko Matsumoto, Yoshiyuki Yamamoto, Takao Tsuduki i in. "Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)". International Journal of Clinical Oncology 27, nr 4 (28.01.2022): 684–94. http://dx.doi.org/10.1007/s10147-022-02114-y.
Pełny tekst źródłaYu, Na, Jun Li, Pankaj Kumar Singh, Dan Ding, Weihao Sun, Qiyun Tang i Huae Xu. "The Superior Anticancer Effect of Reactive Oxygen Species-Responsive Paclitaxel Nanoparticles is Mediated Through Autophagic Cell Death". Journal of Biomedical Nanotechnology 15, nr 11 (1.11.2019): 2251–61. http://dx.doi.org/10.1166/jbn.2019.2847.
Pełny tekst źródłaKimura, Michio, Eiseki Usami, Hitomi Teramachi i Tomoaki Yoshimura. "Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer". Journal of Oncology Pharmacy Practice 24, nr 6 (24.04.2017): 403–11. http://dx.doi.org/10.1177/1078155217707335.
Pełny tekst źródłaHirata, Kenro, Yasuo Hamamoto, Hirokazu Shoji, Hiroki Hara, Chihiro Kondoh, Hisateru Yasui, Takeshi Kajiwara i in. "A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT)." Journal of Clinical Oncology 40, nr 4_suppl (1.02.2022): 280. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.280.
Pełny tekst źródłaZuo, Yangsong, Wenyi Shen, Lili Wang, Chengshi Wang i Juan Pu. "Study on the Mechanism of Action of Paclitaxel-Loaded Polylactic-co-glycolic Acid Nanoparticles in Non-Small-Cell Lung Carcinoma Cells". Computational and Mathematical Methods in Medicine 2022 (6.04.2022): 1–7. http://dx.doi.org/10.1155/2022/8524951.
Pełny tekst źródłaKitayama, Joji, Hironori Ishigami, Hironori Yamaguchi, Jun Yamada, Daisuke Soma, Hideyo Miyato, Takao Kamei, Alan Kawarai Lefor i Naohiro Sata. "Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model". Pleura and Peritoneum 2, nr 2 (27.06.2017): 95–102. http://dx.doi.org/10.1515/pp-2017-0002.
Pełny tekst źródłaHussain, Talib, Sathishbabu Paranthaman, Syed Mohd Danish Rizvi, Afrasim Moin, Devegowda Vishakante Gowda, Gehad Muhammed Subaiea, Mukhtar Ansari i Abulrahman Sattam Alanazi. "Fabrication and Characterization of Paclitaxel and Resveratrol Loaded Soluplus Polymeric Nanoparticles for Improved BBB Penetration for Glioma Management". Polymers 13, nr 19 (22.09.2021): 3210. http://dx.doi.org/10.3390/polym13193210.
Pełny tekst źródłaChiu, Hui-Wen, Jeng-Shou Chang, Hui-Yu Lin, Hsun-Hua Lee, Chia-Hao Kuei, Che-Hsuan Lin, Huei-Mei Huang i Yuan-Feng Lin. "FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer". Journal of Clinical Medicine 7, nr 10 (6.10.2018): 330. http://dx.doi.org/10.3390/jcm7100330.
Pełny tekst źródłaGomes, Fernando L. T., Raul C. Maranhão, Elaine R. Tavares, Priscila O. Carvalho, Maria L. Higuchi, Fernando R. Mattos, Fabio G. Pitta, Sergio A. Hatab, Roberto Kalil-Filho i Carlos V. Serrano. "Regression of Atherosclerotic Plaques of Cholesterol-Fed Rabbits by Combined Chemotherapy With Paclitaxel and Methotrexate Carried in Lipid Core Nanoparticles". Journal of Cardiovascular Pharmacology and Therapeutics 23, nr 6 (20.05.2018): 561–69. http://dx.doi.org/10.1177/1074248418778836.
Pełny tekst źródłaWilke, Hansjochen, Eric Van Cutsem, Sang Cheul Oh, Gyorgy Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto i in. "RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)." Journal of Clinical Oncology 32, nr 3_suppl (20.01.2014): LBA7. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.lba7.
Pełny tekst źródłaSontag, J. M., D. Thierse, B. Rouot, D. Aunis i M. F. Bader. "A pertussis-toxin-sensitive protein controls exocytosis in chromaffin cells at a step distal to the generation of second messengers". Biochemical Journal 274, nr 2 (1.03.1991): 339–47. http://dx.doi.org/10.1042/bj2740339.
Pełny tekst źródłaLi, Lingling, Saitian Zeng, Liang Guo, Ping Huang, Jie Xi, Jing Feng, Qian Li i in. "Long Noncoding RNA RMRP Contributes to Paclitaxel Sensitivity of Ovarian Cancer by Regulating miR-580-3p/MICU1 Signaling". Journal of Oncology 2022 (29.01.2022): 1–10. http://dx.doi.org/10.1155/2022/8301941.
Pełny tekst źródłaYonemaru, M., J. R. Hatherill, H. Hoffmann, H. Zheng, K. Ishii i T. A. Raffin. "Pentoxifylline does not attenuate acute lung injury in the absence of granulocytes". Journal of Applied Physiology 71, nr 1 (1.07.1991): 342–51. http://dx.doi.org/10.1152/jappl.1991.71.1.342.
Pełny tekst źródłaAbu Samaan, Tala M., Marek Samec, Alena Liskova, Peter Kubatka i Dietrich Büsselberg. "Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer". Biomolecules 9, nr 12 (27.11.2019): 789. http://dx.doi.org/10.3390/biom9120789.
Pełny tekst źródłaImai, Hiroo, Keigo Komine, Shin Takahashi, Ken Saijo, Yoshinari Okada, Akihiro Kobayashi, Akira Okita i in. "Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma". Chemotherapy 61, nr 5 (2016): 262–68. http://dx.doi.org/10.1159/000444122.
Pełny tekst źródłaSoe, Zar Chi, Wenquan Ou, Milan Gautam, Kishwor Poudel, Bo Kyun Kim, Le Minh Pham, Cao Dai Phung i in. "Development of Folate-Functionalized PEGylated Zein Nanoparticles for Ligand-Directed Delivery of Paclitaxel". Pharmaceutics 11, nr 11 (30.10.2019): 562. http://dx.doi.org/10.3390/pharmaceutics11110562.
Pełny tekst źródłaGao, Yu, Tao Liu, Xuan Liu i Chao Wu. "Preparation of paclitaxel-folic acid functionalized gelatin grafted mesoporous hollow carbon nanospheres for enhancing antitumor effects toward liver cancer (SMMC-7721) cell lines". Journal of Biomaterials Applications 34, nr 8 (26.12.2019): 1071–80. http://dx.doi.org/10.1177/0885328219896457.
Pełny tekst źródłaKuznetsov, Konstantin, Alena Stepanova, Ren Kvon, Timothy Douglas, Nikita Kuznetsov, Vera Chernonosova, Ivan Zaporozhchenko i in. "Electrospun Produced 3D Matrices for Covering of Vascular Stents: Paclitaxel Release Depending on Fiber Structure and Composition of the External Environment". Materials 11, nr 11 (2.11.2018): 2176. http://dx.doi.org/10.3390/ma11112176.
Pełny tekst źródłaZhong, Aimin, Viswanath Billa, Lorne E. Rotstein, Pui Y. Wong, Joanne M. Bargman, Stephen I. Vas i Dimitrios G. Oreopoulos. "Recurrence of Hyperparathyroidism after Total Parathyroidectomy and Autotransplantation in Peritoneal Dialysis Patients". Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 20, nr 2 (marzec 2000): 200–208. http://dx.doi.org/10.1177/089686080002000207.
Pełny tekst źródłaKimura, Yasue, Tetsuya Kusumoto, Eiji Kusumoto, Masahiko Sugiyama, Mitsuhiko Ohta, Norifumi Tsutsumi, Yoshihisa Sakaguchi i Koji Ikejiri. "The comparison of the usefulness of nab-paclitaxel and paclitaxel for advanced or recurrent gastric cancer." Journal of Clinical Oncology 33, nr 3_suppl (20.01.2015): 217. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.217.
Pełny tekst źródłaZajdel, Alicja, Adam Wilczok, Katarzyna Jelonek, Monika Musiał-Kulik, Aleksander Foryś, Suming Li i Janusz Kasperczyk. "Cytotoxic Effect of Paclitaxel and Lapatinib Co-Delivered in Polylactide-co-Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells". Pharmaceutics 11, nr 4 (6.04.2019): 169. http://dx.doi.org/10.3390/pharmaceutics11040169.
Pełny tekst źródłaYang, Qilei, Chang Zu, Wengang Li, Weiwei Wu, Yunlong Ge, Lingling Wang, Li Wang, Yong Li i Xiuhua Zhao. "Enhanced Water Solubility and Oral Bioavailability of Paclitaxel Crystal Powders through an Innovative Antisolvent Precipitation Process: Antisolvent Crystallization Using Ionic Liquids as Solvent". Pharmaceutics 12, nr 11 (22.10.2020): 1008. http://dx.doi.org/10.3390/pharmaceutics12111008.
Pełny tekst źródłaWei, Yuping, Liang Zhang, Yankai Fu i Xia Xu. "Rapid delivery of paclitaxel with an organic solvent-free system based on a novel cell penetrating peptide for suppression of tumor growth". Journal of Materials Chemistry B 5, nr 37 (2017): 7768–74. http://dx.doi.org/10.1039/c7tb01259d.
Pełny tekst źródłaPan, Wang, Qian Wang, Yi Zhang, Naishu Zhang, Jiamin Qin, Wei Li, Jing Wang, Fangfang Wu, Lingsen Cao i Guanglin Xu. "Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression". Cellular Physiology and Biochemistry 39, nr 2 (2016): 481–90. http://dx.doi.org/10.1159/000445640.
Pełny tekst źródłaPrinetti, Alessandro, Danilo Millimaggi, Sandra D'Ascenzo, Matilda Clarkson, Arianna Bettiga, Vanna Chigorno, Sandro Sonnino, Antonio Pavan i Vincenza Dolo. "Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells". Biochemical Journal 395, nr 2 (28.03.2006): 311–18. http://dx.doi.org/10.1042/bj20051184.
Pełny tekst źródłaNakatani, Yuki, Aya Nakaya, Takayasu Kurata, Takashi Yokoi, Yuki Takeyasu, Maiko Niki, Kayoko Kibata i in. "Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer". Case Reports in Oncology 10, nr 2 (4.08.2017): 683–88. http://dx.doi.org/10.1159/000479148.
Pełny tekst źródłaCui, Hongmei, Kinsie Arnst, Duane D. Miller i Wei Li. "Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance". Current Medicinal Chemistry 27, nr 39 (24.11.2020): 6573–95. http://dx.doi.org/10.2174/0929867326666191016113631.
Pełny tekst źródłaNguyen, Thi Lan, Thi Hiep Nguyen i Dai Hai Nguyen. "Development and In Vitro Evaluation of Liposomes Using Soy Lecithin to Encapsulate Paclitaxel". International Journal of Biomaterials 2017 (2017): 1–7. http://dx.doi.org/10.1155/2017/8234712.
Pełny tekst źródłaRibeiro, Edson A., Luiz F. Poli-de-Figueiredo, Rodrigo Vincenzi, Flavio H. F. Galvao, Nelson Margarido, Mauricio Rocha-e-Silva i Ruy J. Cruz. "Intraportal versus Systemic Pentoxifylline Infusion after Normothermic Liver Ischemia: Effects on Regional Blood Flow Redistribution and Hepatic Ischemia-Reperfusion Injury". HPB Surgery 2013 (29.08.2013): 1–6. http://dx.doi.org/10.1155/2013/689835.
Pełny tekst źródłaKigawa, J., W. Kawaguchi, H. Itamochi, Y. Kanamori, T. Oishi, M. Shimada, S. Sato, S. Sato i N. Terakawa. "Effect of simultaneous inhibition of MEK and PI3K/Akt pathways on paclitaxel sensitivity in ovarian cancer". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 16046. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.16046.
Pełny tekst źródłaCheng, Xingzhen, Fang Yang, Yang Wang, Wei Nie, Adarsha Mahendra Upadhyay, Maolin Zhang, Qian Wang i Zhiqiang Yan. "Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis". Canadian Journal of Gastroenterology and Hepatology 2022 (10.06.2022): 1–14. http://dx.doi.org/10.1155/2022/6015877.
Pełny tekst źródłaZharikov, Sergey I., Karina Y. Krotova, Leonid Belayev i Edward R. Block. "Pertussis toxin activates l-arginine uptake in pulmonary endothelial cells through downregulation of PKC-α activity". American Journal of Physiology-Lung Cellular and Molecular Physiology 286, nr 5 (maj 2004): L974—L983. http://dx.doi.org/10.1152/ajplung.00236.2003.
Pełny tekst źródłaMonroe, J. J., i A. H. Tashjian. "Palytoxin modulates cytosolic pH in human osteoblast-like Saos-2 cells via an interaction with Na(+)-K(+)-ATPase". American Journal of Physiology-Cell Physiology 270, nr 5 (1.05.1996): C1277—C1283. http://dx.doi.org/10.1152/ajpcell.1996.270.5.c1277.
Pełny tekst źródłaMarkeb, Ahmed A., Nagwa A. El-Maali, Douaa M. Sayed, Amany Osama, Mohamed A. Y. Abdel-Malek, Amen H. Zaki, Mostafa E. A. Elwanis i James J. Driscoll. "Synthesis, Structural Characterization, and Preclinical Efficacy of a Novel Paclitaxel-Loaded Alginate Nanoparticle for Breast Cancer Treatment". International Journal of Breast Cancer 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/7549372.
Pełny tekst źródłaXu, Xiaoyan, Chao Wu, Andi Bai, Xuan Liu, Huiling Lv i Ying Liu. "Folate-Functionalized Mesoporous Silica Nanoparticles as a Liver Tumor-Targeted Drug Delivery System to Improve the Antitumor Effect of Paclitaxel". Journal of Nanomaterials 2017 (2017): 1–13. http://dx.doi.org/10.1155/2017/2069685.
Pełny tekst źródłaYang, Haotian, Jun Zhang, Ying Huan, Yawei Xu i Rong Guo. "Pentraxin-3 Levels Relate to the Wells Score and Prognosis in Patients with Acute Pulmonary Embolism". Disease Markers 2019 (12.03.2019): 1–6. http://dx.doi.org/10.1155/2019/2324515.
Pełny tekst źródłaSun, Hongwen, Xiaoting Zhou, Yanan Bao, Guosheng Xiong, Yue Cui i Hua Zhou. "Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer". Open Biology 9, nr 7 (lipiec 2019): 180227. http://dx.doi.org/10.1098/rsob.180227.
Pełny tekst źródłaLiao, Shang-Chih, Sin-Hua Moi, Fong-Fu Chou, Cheng-Hong Yang i Jin-Bor Chen. "Changes in Serum Concentrations of Fibroblast Growth Factor 23 and Soluble Klotho in Hemodialysis Patients after Total Parathyroidectomy". BioMed Research International 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/6453803.
Pełny tekst źródłaAiroldi, M., L. Cattel, R. Passera, P. Milla, L. Delprino, C. Boselli, C. Buffa i F. Pedani. "Paclitaxel and pegylated liposomal doxorubicin in recurrent head/neck cancer: An unexpected administration interval-dependent pharmacokinetic interaction". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 2042. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2042.
Pełny tekst źródła